Trial Profile
An observational study to collect real world data on Chronic inflammatory demyelinating polyneuropathy patients treated with IVIg (Gamunex ® 10%, Grifols) and to assess safety, tolerability, fatigue and depression
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jan 2020
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Adverse reactions; Therapeutic Use
- Acronyms GAMEDIS; GAMEDIS-2
- 29 Jul 2018 New trial record
- 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology